Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1

Inclusion Criteria: * Satisfactory colposcopy examination * Negative endocervical canal by colposcopy * Ectocervical CIN1 as verified by local pathologist (biopsy). * Colposcopical visible lesion at visit 2, before photoactivation * Written Informed Consent signed * Age 18 or above Exclusion Criteria: * Previous treatment of CIN or invasive disease or suspicion of either micro-invasive or invasive disease * Malignant cells on cytology or histology * Atypical glandular cells (AGC) or adenocarcinoma in situ (AIS) on cytology * Suspicion of endocervical disease on colposcopy * Current pelvic inflammatory disease, cervicitis, or other gynecological infection as per colposcopy and clinical examination * Known or suspected porphyria * Known allergy to hexaminolevulinate or similar compounds (e.g. methyl aminolevulinate or aminolevulinic acid) * Use of heart pacemaker * Pregnancy * Nursing * Childbirth or miscarriage within six weeks of enrolment - Known * Participation in other "competitive" clinical studies either concurrently or within the last 30 days * Risk of poor protocol compliance * Not willing to use adequate birth control from screening until last PDT * Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.